| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG criteria due to NICE appraisal TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 25 mg/ml concentrate for solution for infusion |
| Reference number | 4891 |
| Indication | Treatment of HER2 negative advanced gastric or GEJ adenocarcinoma in adults, plus chemotherapy |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/03/2023 |
| NICE guidance | |